GLENMARK’S HISTORIC LICENSING DEAL — BULLETIN UPDATE

The deal also entails $1.23 billion in milestone payments. While

unit IGI will retain rights for India and emerging markets, AbbVie will develop and market ISB 2001 in North America, Europe, Japan, and Greater China Deal Overview Partner: AbbVie Inc. (USA) — a global leader in immunology & oncology Deal Size: $700 million upfront licensing fee Up to $1.23 billion in milestone-based payments (regulatory + commercial milestones) Royalties: Additional tiered royalties on global sales Drug In Focus Name: ISB 2001 Type: Trispecific Antibody Therapy Target Disease: Relapsed/Refractory Multiple Myeloma (Blood Cancer) Mechanism: Targets BCMA, CD38, and CD3 — offering a 3-pronged T-cell engagement strategy Status: Currently in Phase-1 clinical trials Fast Track & Orphan Drug Designation from U.S. FDA Scientific Significance ISB 2001 is part of IGI’s proprietary BEAT platform (Bi-specific Engagement by Antibodies based on the T cell), which allows highly customizable trispecific antibodies Targets patients resistant to current BCMA therapies Designed to overcome immune escape seen in late-stage blood cancer This is a defining moment for Indian biotech. ISB 2001 has world-class potential to reshape cancer treatment, and AbbVie’s partnership validates our BEAT platform.